Amanote Research
Register
Sign In
Pms31 - Secukinumab as a More Eeficient Alternative for Ankylosing Spondylitis Treatment: A Cost Per Responder Analysis From Korean Perspective
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.1745
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
D. Kim
H. Kim
S. Cho
M. Park
Publisher
Elsevier BV
Related search
Pms42 - Secukinumab Versus Adalimumab for the Treatment of Ankylosing Spondylitis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pms29 - Secukinumab Versus Adalimumab in the Treatment of Ankylosing Spondylitis: A Cost Per Responder Analysis Among 52 Weeks From a Tunisian Perspective.
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness Analysis of Secukinumab in Ankylosing Spondylitis: A Canadian Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pss29 - Secukinumab Versus Etanercept for the Treatment of Psoriasis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pss35 - Secukinumab Versus Ustekinumab for the Treatment of Psoriasis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pms28 - Secukinumab Versus Infliximab in the Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis Among 48 Weeks From a Tunisian Perspective.
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pms45 - Cost Per Responder Analysis Following a 48-Week Psoriatic Arthritis Treatment With Secukinumab Versus Adalimumab From the Portuguese Payer Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pms27 - Secukinumab Versus Adalimumab in the Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis Among 48 Weeks From a Tunisian Perspective.
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pss33 - Secukinumab as First Biologic Treatment: A Cost Per Responder Analysis Compared With Licensed Biologics, for Moderate to Severe Psoriasis in Argentina
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
